Karyopharm cuts workforce 20%, explores strategic alternatives including sale

Karyopharm Therapeutics Inc.

Reducing workforce by ~20% as part of ongoing expense management; one-time costs immaterial.
Board evaluating financing, merger/sale, restructuring, or debt refinancing; no deal yet.
Engaged with potential investors under confidentiality; discussions did not result in a transaction.
Committed to Phase 3 trials in myelofibrosis and endometrial cancer.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.